At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Antithrombotics; Small molecules
- Mechanism of Action Fibrinogen receptor antagonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 07 Mar 1996 Discontinued-Preclinical for Thrombosis in Germany (Unknown route)
- 23 Feb 1995 Preclinical development for Thrombosis in Germany (Unknown route)